Pharmaceutical Industry Articles & Reports - Page 4

Analyze the 2026 FDA Accelerated AI Pathway Pilot. Review the regulatory framework and the 10 selected companies advancing AI-discovered drugs to Phase I.

Review the FDA approval of relacorilant (Lifyorli) for platinum-resistant ovarian cancer. Learn its clinical efficacy and mechanism as a GR antagonist.

Examine the Bayer-Perfuse acquisition and the clinical science of PER-001, a novel endothelin receptor antagonist for glaucoma and diabetic retinopathy.

Examine how AI-driven ultra-large virtual screening evaluated 325 billion molecules to identify MDL-4102, a highly selective BRD4 inhibitor for oncology.

Review the 2026 FDA approval of Optune Pax (TTFields) for locally advanced pancreatic cancer. Explore PANOVA-3 trial survival data and mechanism of action.

Examine how leading pharmaceutical companies utilize AI training and workforce upskilling programs to address digital skill gaps in drug discovery operations.

Analyze 2027 drug patent expirations and the impending patent cliff. Review a detailed loss-of-exclusivity (LOE) calendar for biologics and small molecules.

Examine LLM security risks in pharma, including prompt injection and data exfiltration. Review red teaming methods and GxP risk assessments for regulated AI.

Examine the May 2026 GSK-SiranBio licensing deal for SA-030. Learn how this ALK7-targeting siRNA advances GSK's cardiometabolic and oligonucleotide strategy.

Examine the May 2026 White House MFN drug pricing policy. Learn how 17 bilateral pharma agreements and the TrumpRx initiative project $529B in U.S. savings.

Learn about the FDA's new HALO platform and Elsa 4.0 AI system. This guide covers consolidated eCTD submissions, AI review workflows, and sponsor migration.

Examine the April 2026 FDA approval of Idvynso (doravirine/islatravir). Understand this tenofovir-free, two-drug HIV regimen's clinical efficacy and safety.

Analyze Tempus AI's Q1 2026 nine-figure real-world data (RWD) and AI modeling agreements with Merck and Gilead to understand the evolution of RWD pricing.

Analyze the Phase 3 RASolute-302 trial results for daraxonrasib, a novel RAS(ON) inhibitor demonstrating significant survival benefit in pancreatic cancer.

Analyze the HOPE-3 Phase 3 trial results for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. Review PUL v2.0 data and FDA status.

Review the 2026 FDA approval of vepdegestrant (Veppanu), the first PROTAC targeted protein degrader for ESR1-mutated breast cancer, and its clinical data.

Review AstraZeneca's tozorakimab Phase 3 MIRANDA trial results for COPD. This analysis explains IL-33 pathway biology and compares itepekimab clinical data.

Analyze IQVIA's deployment of 192 pharma AI agents across 64 use cases. Learn how top life sciences CIOs benchmark enterprise AI adoption and ROI in 2026.

Analyze the FDA AI early-phase clinical trials RFI. This guide covers pilot program objectives, AI evaluation metrics, and evidence-based response strategies.

Review this educational playbook for Veeva CRM Approved Email implementation. Learn about technical setup, compliance frameworks, HCP engagement, and pitfalls.

Examine Phase 2/3 trial results for TAK-881, a 20% SCIG therapy for primary immunodeficiency offering comparable IgG exposure in half the infusion volume.

Examine AI in pharma HEOR and real-world evidence. This report details how machine learning and RWD advance health economic modeling and regulatory decisions.

Review the FDA full approval of Tecartus for relapsed mantle cell lymphoma. This analysis covers ZUMA-2 Cohort 3 efficacy data, CAR-T safety, and clinical use.

Review the Veeva Vault 26R2 release preview. Learn about mid-2026 platform enhancements, including document viewer upgrades, QMS, RIM, and safety workflows.